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ses). Results: Sixteen economic analyses were included; all studies used deci-
sion-tree structures to model acute prophylaxis, and 13 included a chronic-phase 
Markov module to capture long-term complications and recurrent VTE events. The 
model structures generally captured the important events needed to accurately 
estimate differences in costs and outcomes between different treatment strate-
gies. Eleven studies included rivaroxaban, 9 studies included dabigatran, 3 studies 
included apixaban, and no studies included edoxaban. The analyses that compared 
a NOAC with low molecular-weight heparin (LMWH) predominantly resulted in 
the NOAC dominating LMWH for patients with both THR and TKR. The results of 
analyses that compared NOACs with each other suggested that dabigatran is the 
least cost-effective option. There is limited evidence directly comparing rivaroxaban 
with apixaban, but our results suggested that rivaroxaban dominates apixaban for 
patients with TKR in the United Kingdom. ConClusions: Economic analyses of 
NOACs for primary VTE prophylaxis following THR and TKR surgeries show reason-
able consistency in the model structures used and events captured. The results 
strongly suggest that NOACs are cost-effective alternatives to LMWH. Dabigatran 
appears to be the least cost-effective NOAC. However, more research is needed to 
assess the cost-effectiveness of apixaban and edoxaban.
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Cost-EffECtiVEnEss of fErriC CarboxymaltosE in PatiEnts With iron 
DEfiCiEnCy anD ChroniC hEart failurE in austria
Walter E, Bauer M, Ressl S
Institute for Pharmaeconomic Research, Vienna, Austria
objeCtives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. Two pivotal studies (FAIR-HF and CONFIRM-HF) showed 
that the iron deficiency with ferric carboxymaltose (FCM), an i.v. iron, results in 
clinical meaningful benefits. The purpose of this study was to evaluate the cost-
effectiveness of FCM versus no-treatment and oral iron supplementation in CHF 
patients with iron deficiency w/o anemia. Methods: We developed a Cost-Utility-
Model to simulate disease progression in CHF patients using different strategies of 
iron deficiency management. Markov modelling techniques were used to estimate 
disease progression, based on health states, defined by NYHA classes and death. 
Monte Carlo simulation accounted for uncertainty. The model includes 5 states and 
monthly transitions. Probabilities were derived from clinical and epidemiological 
studies. The cohort definition was adapted from the FAIR-HF study. Direct costs 
(NYHA, inpatient, outpatient and iron treatment costs) from published sources were 
used and expressed in 2014 Euro from the payer’s perspective. QALYs and total costs 
were projected over a 4-year time horizon and discounted at 5% p.a. Results: 
Over a 4-year timeframe, costs and outcomes associated with FCM would amount 
to 18,797.39 € and 2.46 QALYs. Costs associated with oral treatment are 17,307.06 € 
and 2.37 QALYs (ICER per QUALY gained: € 16,921.62). Costs and outcomes associated 
with no-treatment are 17,934.15 € and 2.3 QALYs (ICER per QUALY gained: 5,411.23 € ). 
Due to a delayed disease progression in the FCM group NYHA costs are lower than 
with oral replacement and no-treatment. ConClusions: Iv iron treatment with 
FCM compared with oral iron in iron deficient CHF patients is clearly below the CE 
threshold of € 22.200-€ 33.300/QUALY typically used by the UK NICE and hence can 
be considered a cost efficient treatment strategy.
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ComParison of oVErall Costs bEtWEEn alProstaDil anD limb 
amPutation in PatiEnts affECtED by PEriPhEral artErial DisEasE 
stagEs iii anD iV in mExiCo
Aguirre A1, Carlos F2, Gasca R2, Naranjo M1, Fernandez C1
1UCB, Mexico, Mexico, 2R A C Salud Consultores S.A. de C.V, Mexico City, Mexico
objeCtives: Peripheral arterial disease entails increased mortality besides a sig-
nificant economic and humanistic burden, especially in patients with critical limb 
ischemia (CLI; stages III and IV). Prostanoids are usually indicated to those unsuit-
able for interventional therapy. We aimed to assess the overall costs of alprostadil 
(prostaglandin E1) as treatment for CLI compared with amputation from the per-
spective of the Instituto Mexicano del Seguro Social (IMSS). Methods: Based on 
published literature, information derived from an expert panel, and local official 
sources of unit costs and other parameters, we evaluated three categories of costs: 
acquisition and administration of alprostadil given 40µg twice a day for 28 days; 
surgery, hospital stay, and rehabilitation after amputation; incapacity, prosthesis, 
and pensions in assumed current workers. We conducted the analysis for a time 
frame of one year using a decision tree developed in Microsoft Excel®. We gathered 
the effectiveness of alprostadil from a clinical trial. All costs are expressed in 2014 
Mexican pesos (MXN). We performed a deterministic sensitivity analysis. Results: 
Excluding the prosthesis costs, total direct medical costs of alprostadil were MXN 
4006 (5.8%) lower than the direct medical costs expected with limb amputation 
(MXN 65,490 Vs. MXN 69,496). When costs due to incapacity, prosthesis, and pensions 
in the workforce subpopulation were included into the analysis, the net difference 
in favour of alprostadil reached MXN 8,864 (MXN 66,577 Vs. MXN 75,441) which is 
equivalent to an overall cost reduction of 11.8%. Deterministic sensitivity analysis 
showed the model is quite sensitive to the acquisition and intra-arterial costs of 
alprostadil. ConClusions: Acquisition and administration costs of alprostadil 
may be offset by the overall savings in direct medical costs and in payments due 
to incapacities and pensions.
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PharmaCoEConomiC analysis of Various trEatmEnt stratEgiEs for 
PatiEnts With ChroniC VEnous insuffiCiEnCy of thE loWEr limbs
Ryazhenov VV1, Gorokhova SG2, Gorokhov V2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Research Clinical Center 
of JSC Russian Railways, Moscow, Russia
objeCtives: Determining pharmacoeconomic efficiency of actovegin in complex 
therapy of complicated chronic venous disease of lower extremities. Methods: 
old of £30,000. ConClusions: At a willingness-to-pay threshold of £20,000 per 
QALY, all NOACs are cost-effective compared with warfarin. There is considerable 
uncertainty between the different NOACs, but apixaban (5mg bd) had the highest 
expected incremental net benefit and the highest probability (60%) of being most 
cost-effective first line anticoagulant for the prevention of stroke in AF, primarily 
due to lower rates of intracranial haemorrhage, other clinically relevant bleeding, 
and myocardial infarction.
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objeCtives: To assess the cost-effectiveness of edoxaban versus acenocoumarol 
(VKA treatment) in the prevention of stroke and systemic embolic events in patients 
with non-valvular atrial fibrillation (NVAF) in Spain. Methods: A Markov model 
was developed and adapted to the Spanish setting to simulate the evolution of 
NVAF patients throughout their lifetime. The Cycle length was 1 month and differ-
ent health states such as stroke, bleeding and other cardiovascular complications 
were defined to mimic NVAF natural history. Drug’s safety and efficacy outcomes 
were obtained from the Phase III trial. The analysis was conducted from the Spanish 
National Health System (NHS) perspective. Edoxaban and acenocoumarol costs were 
calculated according to recommended doses. The costs of NVAF complications and 
disease management costs were obtained from available Spanish published sources. 
An annual discount of 3% for costs and health outcomes was applied. Results: 
Edoxaban resulted on average with 0.337 quality-adjusted life-years (QALYs) gained 
and 0.285 life years gained (LYG) compared with acenocoumarol. Due to the pro-
jected longer survival of patients, edoxaban could generate more costs per patient 
than acenocoumarol from the NHS perspective, but the incremental cost-effective-
ness ratio (ICER) for edoxaban was highly cost effective, at 7,888€ per LYG and 6,671 € 
per QALY gained. To evaluate study robustness subgroup analyses (such CHADS2> 3 
score and percentage of well controlled patients), and probabilistic sensitivity analy-
ses were performed. Those analyses confirmed the ICERs for edoxaban to be cost-
effective when applying the commonly accepted cost effectiveness threshold in 
Spain. ConClusions: Edoxaban is cost-effective compared with acenocoumarol 
from the NHS perspective in the prevention of stroke and systemic embolic events 
in patients with NVAF in Spain.
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for DEEP VEnous thrombosis Without Pulmonary Embolism
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objeCtives: Deep venous thrombosis (DVT) and pulmonary embolism (PE) com-
prise venous thromboembolism (VTE), the third most common cardiovascular ill-
ness after acute coronary syndrome and stroke and a raising public health concern 
due to its morbity and mortality and higher costs. Acute and long term treatments 
help to avoid complications. We assessed the costs and effectiveness of different 
regimens for treatment of DVT without PE under the perspective of the Mexican 
public health system. Methods: A seven-pathway decision tree allowed compari-
son of five competing strategies. Acute treatment for 7 days involved bemiparin 
115UI/Kg once daily (BEM), enoxaparin 1.5mg/Kg once daily (ENO-OAD), enoxaparin 
1.0 mg/Kg twice daily (ENO-BID), nadroparin 100UI/Kg twice daily (NAD) or unfrac-
tionated heparin administered as 80UI/Kg initial bolus followed by continuous 
infusion at a rate of 18/UI/Kg/hour (UFH). Long-term treatment consisted of daily 
doses of warfarin 5 mg given orally during 83 days (VKA). Direct medical costs 
included acquisition of medicines, care of further VTE episodes, and managing 
of adverse events/complications. Resource use was based on published literature 
and expert´s opinion. Local unit costs and diagnosis-related groups (DRG) costs 
were gathered. Effectiveness is expressed in terms of VTE-free patients and deaths 
avoided per 1000 treated. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: Acute treatment with BEM was the most-effective interven-
tion with benefits ranging from 33 VTE-free patients and 7 deaths avoided (Vs. 
ENO-OAD and ENO-BID, respectively) to 64 VTE-free patients and 21 deaths avoided 
(both Vs. NAD) per 1,000 treated. BEM followed by warfarin was also the less costly 
regimen leading to overall cost-savings varying between MXN$3,067,626 (Vs. NFH) 
and MXN$7,084,142 (Vs. NAD) per 1,000 treated. Model results were robust to plau-
sible changes in main parameters. ConClusions: Bemiparin may present a cost 
saving alternative over the use of other low molecular weight heparins or UFH as 
initial therapy for patients affected by DVT without PE.
PCV106
EConomiC EValuations of nEW oral antiCoagulants for thE 
PrEVEntion of VEnous thromboEmbolism aftEr total hiP or total 
KnEE rEPlaCEmEnt
Brockbank J, Wolowacz S
RTI Health Solutions, Manchester, UK
objeCtives: The objectives of this systematic review were to identify published 
economic analyses of new oral anticoagulants (NOACs) for primary venous throm-
boembolism (VTE) prophylaxis following total hip replacement (THR) and total knee 
replacement (TKR) surgeries and to summarise the modelling techniques used and 
cost-effectiveness results. Methods: Electronic searches of MEDLINE, EconLit, and 
the Cochrane Library were performed from January 2008 to February 2015 using a 
combination of Medical Subject Headings and free-text terms that were grouped 
into the following categories: population (including terms for thromboembolism 
and orthopaedic surgery), intervention (including terms for apixaban, dabigatran, 
edoxaban, and rivaroxaban), and study design (including terms for economic analy-
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lation (AF). It is therefore relevant to evaluate NOACs relative cost-effectiveness 
in Portuguese AF patients. Methods: A Markov model was used to analyze the 
disease progression over a lifetime horizon. Relative efficacy data for stroke 
(ischemic and hemorrhagic), bleeding (intracranial, other major bleeds and clini-
cally relevant non-major bleeds), myocardial infarction and treatment discontinu-
ation were used by means of pairwise indirect treatment comparisons between 
apixaban, dabigatran and rivaroxaban using warfarin as a common comparator. 
Resource use was obtained from Diagnosis Related Group legislation data base and 
an expert panel. Model outputs included life years gained, quality-adjusted life 
years (QALYs), direct healthcare costs and incremental cost-effectiveness ratios 
(ICERs). Results: Apixaban provided the highest life years gained and QALYs. The 
apixaban ICER versus warfarin and dabigatran was 5,529€ /QALY and 9,163€ /QALY, 
respectively. Apixaban was dominant versus rivaroxaban (higher health gains and 
lower costs). Results were robust over a wide range of inputs in sensitivity analy-
ses. Apixaban had a 70% chance of being cost-effective (at a threshold of 20,000€ /
QALY) versus the set of all other therapeutic options. ConClusions: Apixaban 
is a cost-effective alternative to warfarin and dabigatran and is dominant versus 
rivaroxaban in AF patients from a Portuguese national healthcare system perspec-
tive. These conclusions are based on indirect treatment comparisons. Despite 
this limitation, this information is relevant for different health care decision 
makers.
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Dabigatran for thE trEatmEnt anD sEConDary PrEVEntion of VEnous 
thromboEmbolism
Stevanovic J1, Kappelhoff B2, Voorhaar M3, Postma MJ1
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objeCtives: Dabigatran was proven to have similar effect on the recurrence of 
venous thromboembolism (VTE) and a lower risk of bleeding compared to vita-
min K antagonists (VKAs). This study aims to assess the cost-effectiveness (CE) 
of dabigatran for the treatment and secondary prevention in high risk patients 
of VTE compared to VKAs in the Dutch setting. Methods: Previously published 
Markov model was modified and updated to assess the CE of dabigatran and VKAs 
for the treatment and secondary prevention in high risk patients of VTE from a 
societal perspective in the base-case analysis. The model was populated with 
efficacy and safety data from major dabigatran trials (i.e. RE-COVER, RECOVER II, 
RE-MEDY and RE-SONATE), Dutch specific costs, and utilities derived from dabi-
gatran trials or other published literature. Univariate, probabilistic sensitivity 
and a number of scenario analyses on the impact of various decision-analytic 
settings (e.g. the perspective of analysis, use of anticoagulants only for treat-
ment or only for secondary prevention) were tested on the incremental cost-
effectiveness ratio (ICER). Results: In the base-case, patients on dabigatran 
gained an additional 0.583 discounted quality adjusted life years (QALYs) over 
a lifetime and savings of € 1,996. Results of univariate sensitivity analysis were 
quite robust. The probability that dabigatran is cost-effective at a willingness-
to-pay threshold of € 20,000/QALY was 100%. Except for the scenario comparing 
dabigatran to VKAs from the healthcare provider perspective and the one com-
paring dabigatran to placebo for the prevention of recurrent VTE in patients who 
are at equipoise for anticoagulation treatment where the ICERs for dabigatran 
compared to VKAs of € 1,005 and € 33,305 per QALY gained, respectively were esti-
mated, other scenarios showed dabigatran was cost-saving. ConClusions: From 
a societal perspective, dabigatran is likely to be a cost-effective or even cost-saving 
strategy for treatment and secondary prevention of VTE compared to VKAs in the 
Netherlands.
PCV114
a PolyPill intErVEntion to imProVE aDhErEnCE for sEConDary 
CarDioVasCular DisEasE PrEVEntion in sPain: a Cost-EffECtiVEnEss 
stuDy
Arrabal N, Kaskens L, Garcia-Alonso F, Gracia A
Ferrer internacional, Barcelona, Spain
objeCtives: To estimate the health benefits and cost-effectiveness of a polypill 
intervention (100mg aspirin, 20mg atorvastatin and 10mg ramipril) for the second-
ary prevention of cardiovascular (CV) events in adults with a history of myocardial 
infarction (MI) from the perspective of the Spanish health system compared with 
multiple monotherapy. Methods: A Markov model was developed to estimate 
health outcomes, costs and incremental cost-effectiveness ratio (ICER) per LY 
gained and per QALY gained using a 10-year time horizon. The patient population 
included were men and women with an average age of 64.7 years, a history of 
MI and an indication for secondary prevention treatment. Patients in the model 
have a 3-month probability cycle to have one of the following five CV events: acute 
coronary syndrome, non-fatal stroke, non-fatal congestive heart failure requir-
ing hospitalization, unplanned revascularization procedures, or (non-)CV death. 
Model inputs on efficacy, utility and adherence were obtained from systematic 
reviews. Different scenarios were modelled using different sources for acute event 
costs and alternative prices for polypill and its monocomponents. Probabilistic 
analyses were performed to test the robustness of the results. Results: Polypill 
showed to prevent 45 CV fatal and non-fatal events per 1,000 patients in Spain 
in the base case. Total LYs and QALYs gained were 38 and 36 respectively, show-
ing polypill was the dominant strategy. Probabilistic sensitivity analyses for the 
base-case assumptions showed a 90.1% chance of the polypill being cost-effec-
tive at a willingness-to-pay threshold of € 30,000 per QALY gained compared with 
multiple monotherapy. Alternative scenario analyses showed that the polyp-
ill resulted to be dominant or cost-effective in all scenarios. ConClusions: 
The polypill intervention appears to be the dominant or cost-effective strategy 
versus its monocomponents taken separately, showing it can prevent fatal and 
non-fatal CV events in the Spanish population as well as to reduce healthcare 
costs.
A pharmacoeconomic model of administering actovegin in female patients with 
chronic venous disease of lower extremities was developed on the basis of clini-
cal data (Uchkin IG et al.). Three strategies of complex therapy were considered in 
three groups of 100 patients each: 1st group — standard management, 2nd group 
— standard management + local actovegin, 3rd group — standard management + 
both intravenous and local actovegin. Criteria of efficiency were defined as removal 
of heavy legs syndrome and wound healing. Costs of drug administration, hospi-
talization and lab tests were under consideration. The time horizon equalled 1 
month. Results: We determined costs of patient management for each of the 
groups. The costs constituted 8 732 092,50 RUB in the 1st group, 8 543 937,88 RUB in 
the 2nd group, and 8 860 710,75 RUB in the 3rd group, so they did not vary consider-
ably. The cost effectiveness for the removal of heavy legs syndrome in the standard 
therapy group was equal to 14 895,97, while it constituted 10 744,87 and 11 826,97 
in the second and third groups, respectively. CER values considering the number 
of patients with wound healing were 39 482,20 for the 1st group, and 26 889,65 and 
15 689,74 for the 2nd and 3rd groups, respectively. ConClusions: Actovegin in 
complex therapy of complicated chronic venous disease of lower extremities is 
substantiated from the pharmacoeconomic standpoint of cost effectiveness ratio.
PCV110
CliniCal anD EConomiC analysis of EffECtiVEnEss of fonDaParinux 
soDium in thE trEatmEnt of aCutE Coronary synDromE
Krasnova L1, Vorobiev P2, Tyurina I1, Shiganov S1
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Sechenov Moscow State Medical University, Moscow, Russia
objeCtives: Acute coronary syndrome is a “vehicle diagnosis”, the ambulance 
service and involves unstable angina, myocardial infarction, including – without 
segment elevation of ST segment. Aim of this study was to conduct clinical and 
economic analysis of application of fondaparinux sodium and enoxaparin sodium 
in the treatment of acute coronary syndrome. Methods: The method of modeling 
with decision-tree model and “cost-effectiveness” ratio were used. Endpoints were: 
mortality, the onset of myocardial infarction in the 9th, 30th and 180th day from 
the start of the study regarding the side effects in patients with acute coronary 
syndrome based on the results of clinical trials OASIS-5. Calculating the cost of drugs 
and medical services was conducted according to experts and standard of medi-
cal care. Results: The cost of treatment of a single patient with acute coronary 
syndrome with fondaparinux sodium were lower compared with enoxaparin 
sodium to 9th, 30th and 180th day of treatment at 38 € , 42 € and 36 € , respectively. 
The cost-effectiveness ratio on the criterion of “the likelihood of myocardial infarc-
tion” for fondaparinux and enoxaparin on the 9th day of treatment was 5210 € and 
6641 € , on the 30th day - 4084 € and 4810 € , on the 180th day - 3396 € and 3939 € , 
respectively. The cost-effectiveness ratio on the criterion “probability of death” for 
fondaparinux and enoxaparin on the 9th day of treatment was 7525 € and 9088 € , 
on the 30th day - 5351 € and 5635 € , on the 180th day - 3839 € and 4171 € , respec-
tively. ConClusions: The use of fondaparinux sodium is the dominant technology 
in myocardial infarction without lifting ST segment, other direct anticoagulants are 
assigned only in case of its absence.
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thE Cost-EffECtiVEnEss of bariatriC surgEry in gErmany
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objeCtives: Patients eligible for bariatric surgery in Germany often do not receive 
this treatment, and sometimes receive no medical care for their obesity at all as 
the conventional care (CC) of behaviour/activity programmes are not reimbursed 
by the sickness funds. Methods: We developed a Markov model to estimate the 
long-term (20 year) outcomes and costs for patients who receive bariatric surgery 
(gastric bypass or sleeve gastrectomy), CC, or no care (NC), from a German health-
care perspective. Body mass index (BMI) change, type II diabetes mellitus (T2DM), 
stroke, myocardial infarction and cancer were all included; inputs for these were 
taken from recent network meta-analyses. Utilities and costs were sourced from 
the literature and the German DRG tariff. It was assumed that NC patients had 
no obesity care costs and remained at baseline BMI, blood pressure and choles-
terol level. The populations considered were patients with BMI≥ 40 or BMI≥ 35 with 
obesity-related comorbidities, and the subpopulation of T2DM patients. Costs and 
outcomes were discounted at 3% yearly. Results: Compared to those receiving CC 
and NC, patients undergoing bariatric surgery were found to live longer and have 
fewer cases of stroke (-11 and -9 cases per 1000 patients, respectively), myocardial 
infarction (-35 and -41 cases per 1000 patients, respectively) and cancer (-17 cases 
per 1000 patients for both). The difference between bariatric surgery patients and 
CC or NC was even greater in patients with T2DM. Bariatric surgery was found to 
have an ICER of € 361 per QALY versus CC (incremental cost € 921, QALY gain 2.55) 
and of € 812 per QALY versus NC (incremental cost € 2055, QALY gain 2.53). Bariatric 
surgery was associated with an ICER of less than € 10,000/QALY in 100% of simula-
tions versus both CC and NC. ConClusions: Bariatric surgery improves patient 
outcomes and is cost-effective in Germany compared to conventional or no care.
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objeCtives: Recently, three novel non-vitamin K antagonist oral anticoagulants 
(NOACs) got reimbursed in Portugal for patients with non-valvular atrial fibril-
